Retrophin, Inc. (RTRX) Given Average Rating of “Buy” by Analysts

Shares of Retrophin, Inc. (NASDAQ:RTRX) have been given a consensus recommendation of “Buy” by the six brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $36.00.

A number of equities research analysts have commented on the company. ValuEngine lowered Retrophin from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. BMO Capital Markets restated a “buy” rating and set a $44.00 price objective on shares of Retrophin in a research report on Friday, October 6th. Finally, BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://stocknewstimes.com/2017/11/11/retrophin-inc-rtrx-given-average-rating-of-buy-by-analysts.html.

In other news, COO Neil F. Mcfarlane sold 1,378 shares of Retrophin stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total transaction of $31,005.00. Following the completion of the sale, the chief operating officer now directly owns 13,622 shares in the company, valued at approximately $306,495. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 2.41% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC lifted its holdings in shares of Retrophin by 1.8% during the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 146 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Retrophin by 4.3% during the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 355 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Retrophin during the 2nd quarter valued at about $246,000. GSA Capital Partners LLP acquired a new stake in shares of Retrophin during the 2nd quarter valued at about $279,000. Finally, Voya Investment Management LLC lifted its holdings in shares of Retrophin by 11.8% during the 2nd quarter. Voya Investment Management LLC now owns 17,905 shares of the biopharmaceutical company’s stock valued at $347,000 after buying an additional 1,891 shares during the last quarter.

Retrophin (NASDAQ:RTRX) opened at 23.82 on Friday. The firm’s market cap is $914.33 million. The stock’s 50 day moving average is $24.05 and its 200-day moving average is $20.70. Retrophin has a 1-year low of $15.55 and a 1-year high of $25.44.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.10). Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The business had revenue of $38.80 million for the quarter, compared to analyst estimates of $37.36 million. During the same quarter in the previous year, the business posted $0.07 earnings per share. The company’s revenue was up 16.5% compared to the same quarter last year. Analysts forecast that Retrophin will post ($1.13) EPS for the current year.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply